Publications by authors named "Sinem Akbas"

Claim this Profile
E
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study.
İlknur Deliktaş Onur, Mutlu Doğan, Mehmet Akif Öztürk, Taha Koray Sahin, Murat Kiracı

Curr Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study.
Safa Can Efil, Burak Bilgin, Irem Bilgetekin, Kaan Helvaci, Teoman Sakalar, Sinem Akbas

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.
Alper Turkel, Ece Baydar, Rümeysa Çolak, Ahmet Emin Öztürk, Teoman Şakalar

In Vivo· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study.
Selin Akturk Esen, Ismet Seven, Gonca Akdere Ates, Rumeysa Colak, Oğuzcan Kinikoglu, Sinem Akbas

Anticancer Drugs· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.
Özgecan Dülgar, Sema Türker, Gül Başaran, Murat Araz, Ahmet Taner Sümbül

J Chemother· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.
Ozkan Alan, Tugba Akın Telli, Sinem Akbas, Selver Isik, Eyyüb Çavdar

Medicina (Kaunas)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey.
Gul Sema Yildiran Keskin, Ozge Yetginoglu, Sertac Vurgun, Evrican Zin Guzel, Fariz Emrah Ozkan, Sinem Akbas

Medicina (Kaunas)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, Muslih Ürün, Berrak Mermit Erçek

Sci Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG).
Nargiz Majidova, Sendag Yaslıkaya, Maral Martin Mıldanoglu, Alper Coskun, Duygu Ercan Uzundal, Sinem Akbas

Turk J Gastroenterol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group.
Nadiye Sever, Fatih Şimşek, İlknur Deliktaş Onur, Hayati Arvas, Tural Guliyev

J Clin Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study.
Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Sinem Akbas

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.
Serhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, Cihan Erol, Fahriye Tugba Kos, Sinem Akbas

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group.
Arif Akyildiz, Melis Gultekin, Ecem Yigit, Ecem Demir, Rashad Ismayilov, Sinem Akbas

Int J Gynecol Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study.
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, Dilek Erdem, Mehmet Ali Nahit Sendur, Sinem Akbas

Cancers (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Sinem Akbas

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı

BMC Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı

BMC Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study.
Okan Avcı, Yakup İriağaç, Eyyüp Çavdar, Kubilay Karaboyun, Murat Araz

J Geriatr Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.
Arif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, Rashad Ismayilov, Emel Mutlu, Sinem Akbas

Medicine (Baltimore)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Esra Arslan, Nurhan Ergül, Ediz Beyhan, Özge Erol Fenercioglu, Rahime Sahin, Sinem Akbas

Nucl Med Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
Mustafa Gürbüz, Yasin Kutlu, Erman Akkuş, Elif Berna Köksoy, Naziyet Köse

J Cancer Res Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Cihan Erol, Mehmet Ali Nahit Sendur, Irem Bilgetekin, Duygu Bayir Garbioglu, Jamshid Hamdard, Sinem Akbas

J Cancer Res Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis